Heterologous vaccination, here are the best mix and match
A British study confirms that heterologous vaccination gives excellent results. All the details
A major British study on heterologous vaccination of Covid vaccines found that people had a better immune response when they received a first dose of AstraZeneca or Pfizer followed by Moderna nine weeks later.
"We found a really good immune response across the board, above the Oxford-AstraZeneca threshold with two doses," Matthew Piton, the Oxford professor behind the study called Com-COV2, told Reuters .
The findings will offer some hope to poor and middle-income countries that may need to combine different brands of the first and second vaccine if supplies run out or become unstable.
"I think the data from this study will be particularly interesting and valuable for low- and middle-income countries where they are still distributing the first two doses of vaccines," said Snape. "We are demonstrating that it is not necessary to receive the same vaccine for a second dose and that if the program will move forward faster using different vaccines then it is good to do so."
According to Oxford University researchers, if the AstraZeneca vaccine is followed by a dose of Moderna or Novavax, the immune response is better.
The study of 1,070 volunteers also found that one dose of Pfizer followed by one of Moderna was better than two doses of Pfizer.
Pfizer followed by Novavax produced more antibodies than the double dose of AstraZeneca, although the antibody and T cell response was lower than with two doses of Pfizer.
According to the Oxford University study published in The Lancet , there were no safety concerns.
Many countries used mix and match well before solid data was available, as nations faced soaring numbers of infections, low supplies, and slow immunization for some safety concerns.
The duration of protection offered by vaccines has been under scrutiny, with booster doses also considered among cases increasing. The new variants, including Delta and Omicron, have now increased the pressure to speed up vaccination campaigns.
The findings may also provide new approaches to immunization against other diseases, the study says.
The researchers also found that a first dose of AstraZeneca followed by any of the other candidates in the study generated a particularly robust response, consistent with the June results.
The study was designed as a so-called "non-inferiority" study – the intent is to demonstrate that heterologous vaccination is not substantially worse than standard programs – and compares the immune system's responses to gold-standard responses reported in previous studies. of each vaccine.
(Extract from the foreign press review by eprcomunicazione )
This is a machine translation from Italian language of a post published on Start Magazine at the URL https://www.startmag.it/sanita/vaccinazione-eterologa-ecco-quali-sono-i-migliori-mix-and-match/ on Sat, 11 Dec 2021 06:49:17 +0000.